Is there a genetic test available to detect enzyme deficiencies?

Testing for Genetic Enzyme Deficiencies

Yes, both enzymatic activity assays and molecular genetic testing are available to detect enzyme deficiencies, with the optimal diagnostic approach combining both methods for comprehensive evaluation. 1

Diagnostic Testing Approaches

Enzymatic Activity Testing

Enzymatic assays measure the functional activity of specific enzymes and serve as the primary diagnostic method for most enzyme deficiencies. These tests can be performed on various sample types 1:

• Red blood cells (RBCs) from heparinized whole blood
• Cultured fibroblasts
• Dried blood spots (DBS) for newborn screening
• Leukocytes (white blood cells)
• Plasma for certain conditions

Key advantages: Enzymatic testing directly measures functional enzyme deficiency and is essentially diagnostic when significantly decreased activity occurs alongside consistent clinical findings and positive family history 1.

Molecular Genetic Testing

DNA analysis identifies pathogenic variants in genes encoding specific enzymes. Methods include 1:

• Single-gene sequencing
• Next-generation sequencing panels
• Whole exome or genome sequencing
• Copy-number analysis

Critical role: Molecular testing confirms enzymatic diagnoses, identifies pathogenic variants for family screening, clarifies variants of uncertain significance, and detects pseudodeficiency alleles 1.

When Each Test Type Is Preferred

Use Enzymatic Testing First When:

• Clinical suspicion is high for a specific enzyme deficiency
• Newborn screening suggests an abnormality 2
• Confirming molecular findings 1

Use Molecular Testing First When:

• Patient has received recent blood transfusion (donor enzyme activity can persist up to 4 months) 2
• Multiple enzyme deficiencies are possible
• Enzymatic results are inconclusive or contradictory 1

Important Diagnostic Pitfalls

Enzymatic Testing Limitations:

1. Gender-specific issues: Over 60% of heterozygous females with G6PD deficiency show normal enzyme levels and would be missed by enzymatic screening alone 3

2. Tissue-specific variability: For pyruvate dehydrogenase complex deficiency, fibroblast testing shows 97% sensitivity in females versus only 36% sensitivity in lymphocytes 4

3. False results from:

   • Recent blood transfusions 2
   • Sample storage conditions (temperature, humidity) 2
   • Technical errors in assay performance 1
   • Pregnancy, oral contraceptives, diabetes, liver dysfunction 1

4. Normal enzyme activity despite disease: Cofactor or activator deficiencies (GM2 activator deficiency, saposin deficiencies) can cause disease with normal enzyme measurements 1

Molecular Testing Limitations:

• Cannot detect large deletions or deep intronic mutations with standard sequencing 5
• Variants of uncertain significance require enzymatic confirmation 5
• Genotype-phenotype correlations are often weak 6

Recommended Diagnostic Algorithm

For suspected enzyme deficiency:

1. Initial evaluation: Obtain enzymatic activity assay on appropriate tissue (typically RBCs or fibroblasts) 1

2. If enzyme activity is decreased:

   • Repeat testing on second sample to exclude technical error 1
   • Test at least one other enzyme with similar stability profile 1
   • Proceed with molecular testing to identify pathogenic variants 1
   • Consider biomarker studies when available 1

3. If enzyme activity is normal but clinical suspicion remains high:

   • Consider cofactor/activator deficiencies 1
   • Proceed directly to molecular testing 1
   • Evaluate for multiple enzyme deficiencies 1

4. If molecular variants identified first:

   • Confirm with enzymatic testing 1
   • Use biomarker studies to clarify variants of uncertain significance 1

For carrier screening: Enzymatic testing is reliable only for Tay-Sachs disease with established reference ranges; molecular testing should be used for all other enzyme deficiencies 1.

Complementary Testing

Additional supportive tests include 1:

• Urine screening (mucopolysaccharides, oligosaccharides, sulfatides)
• Disease-specific biomarkers (lyso-Gb3 for Fabry, psychosine for Krabbe, glucosylsphingosine for Gaucher)
• Coagulation factors and liver function tests for certain disorders 7

The combination of enzymatic and molecular testing provides superior diagnostic accuracy compared to either method alone 5, 8, with each approach compensating for the limitations of the other.